Comprehensive Clinical Guide: Placenta Accreta Spectrum (PAS) – Focus on Placenta Percreta

1. Introduction and Clinical Overview

Placenta Accreta Spectrum (PAS) represents a critical clinical entity in modern obstetrics, characterized by the abnormal adherence or invasion of the placenta into the uterine wall. Among this spectrum, Placenta Percreta represents the most severe and life-threatening manifestation. In percreta, the chorionic villi penetrate through the entire thickness of the myometrium, extending into the uterine serosa and frequently invading adjacent pelvic organs, most commonly the urinary bladder.

The clinical significance of PAS has escalated globally, paralleling the rising rates of cesarean sections. Historically rare, the incidence now approaches 1 in 272 pregnancies in high-resource settings. Without proactive multidisciplinary management, the mortality and morbidity associated with percreta—primarily massive obstetric hemorrhage (MOH), disseminated intravascular coagulation (DIC), and multi-organ failure—are profound.

2. Pathophysiology and Etiology

The Mechanism of Invasion

The fundamental pathophysiology of PAS is believed to be rooted in a defective decidualization of the uterine lining, specifically at the site of a prior cesarean scar. When the decidua basalis is absent or deficient, the trophoblastic cells are permitted to invade the myometrium without the physiological "stop signal" provided by Nitabuch’s layer.

• The "Scar-Tissue" Theory: The most significant risk factor is a placenta implanted over a prior cesarean section scar. The healing process of the scar results in a localized area of fibrous tissue rather than mature, vascularized endometrium.
• Trophoblastic Hyper-Invasion: In percreta, the invasion is not merely superficial. The trophoblasts undergo an aggressive epithelial-to-mesenchymal transition (EMT), secreting proteases that degrade the myometrial extracellular matrix, allowing the placenta to breach the serosa.

Etiological Drivers

3. Clinical Staging and Grading

The classification of PAS has evolved from simple descriptive terms to a more rigorous histological and clinical framework.

The FIGO Clinical Grading System

The International Federation of Gynecology and Obstetrics (FIGO) utilizes a clinical grading system that helps guide the surgical approach:

• Grade 1 (Accreta): Placenta is adherent to the myometrium.
• Grade 2 (Increta): Placenta invades the myometrium.
• Grade 3 (Percreta):
  • 3a: Penetration of the uterine serosa.
  • 3b: Invasion of the urinary bladder.
  • 3c: Invasion of other pelvic organs (e.g., rectum, broad ligament).

4. Standard Presentation and Diagnosis

Clinical Presentation

PAS is frequently asymptomatic during the pregnancy itself. However, warning signs include:
1. Painless vaginal bleeding in the third trimester (if associated with previa).
2. Hematuria (in cases of bladder invasion).
3. Abdominal pain (rare, usually associated with uterine rupture or impending rupture).

Diagnostic Modalities

Early detection is the cornerstone of mortality reduction.

• Transvaginal Ultrasound (TVUS): The gold standard for initial screening. Key features include "lacunae" (moth-eaten appearance of the placenta), loss of the "clear zone" (hypoechoic retroplacental space), and bladder wall interruption.
• Magnetic Resonance Imaging (MRI): Employed when ultrasound findings are equivocal or to assess the degree of extra-uterine invasion (e.g., bladder or parametrial involvement). MRI is superior for deep pelvic mapping.
• Biomarkers: While maternal serum AFP levels are often elevated, they lack the sensitivity and specificity required for diagnostic confirmation.

5. Clinical Management and Surgical Strategy

The Multidisciplinary Team (MDT)

Management of a confirmed percreta case must occur in a tertiary care center. The MDT must include:
* Obstetricians (specializing in PAS).
* Gynecologic Oncologists (or surgeons with extensive pelvic experience).
* Urologists (if bladder involvement is suspected).
* Interventional Radiologists (for balloon occlusion or embolization).
* Anesthesiologists (experienced in massive hemorrhage protocols).

Surgical Intervention

The standard of care is a planned cesarean hysterectomy with the placenta left in situ.
1. Incision: A high vertical uterine incision is often required to avoid the placenta.
2. Delivery: The fetus is delivered, and the umbilical cord is ligated close to the placenta.
3. Hysterectomy: The uterus is removed en bloc with the placenta, often involving the resection of the bladder wall if the percreta has invaded the detrusor muscle.

6. Risks, Side Effects, and Contraindications

Maternal Risks

• Massive Hemorrhage: Average blood loss in percreta cases often exceeds 3,000–5,000 mL.
• Coagulopathy: DIC is a high-risk complication due to the consumption of clotting factors.
• Ureteric Injury: Risk of iatrogenic damage to the ureters during bladder dissection.
• Post-Traumatic Stress Disorder (PTSD): High incidence of psychological trauma following near-miss obstetric events.

Contraindications for Conservative Management

Conservative management (attempting to leave the uterus and placenta to resorb) is highly controversial and generally contraindicated in cases of percreta due to:
* High rates of delayed hemorrhage.
* Severe septicemia.
* High risk of emergency hysterectomy under suboptimal conditions.

7. Prognosis and Long-Term Outlook

The prognosis for the fetus is generally good if the delivery is timed appropriately (usually 34 0/7 to 35 6/7 weeks). The maternal prognosis is dependent on the speed of intervention and the availability of blood products.

• Short-term: Recovery is often complicated by ICU stays and potential bladder reconstruction.
• Long-term: Patients are typically advised against future pregnancies due to the extreme risk of recurrence and life-threatening surgical complications. Fertility is permanently compromised due to the requirement of hysterectomy.

8. Massive FAQ Section

1. What is the difference between Accreta, Increta, and Percreta?

Accreta involves attachment to the myometrium, Increta involves invasion into the myometrium, and Percreta involves the placenta growing through the uterine wall into adjacent organs.

2. Can Placenta Percreta be cured without a hysterectomy?

In rare, highly selected cases, conservative management is attempted, but it carries a very high risk of maternal death and is not the standard of care for Percreta.

3. How early can Placenta Percreta be detected?

With high-resolution ultrasound, signs can be identified as early as the late first trimester, though the second trimester (18–24 weeks) is the optimal window for screening.

4. Why is the bladder at risk?

The bladder sits immediately anterior to the lower uterine segment. As the placenta grows through the uterine wall, it naturally invades the bladder wall, which is the path of least resistance.

5. What is the role of Interventional Radiology?

Interventional radiologists may place prophylactic balloons in the internal iliac arteries to reduce blood flow to the uterus during the hysterectomy, although evidence on their efficacy is mixed.

6. Are there specific symptoms of Percreta?

Most patients are asymptomatic. Any painless bleeding in the third trimester in a patient with a prior cesarean section should be investigated for PAS.

7. Does Percreta affect the baby?

The condition itself does not directly harm the fetus, but the need for preterm delivery (to avoid labor-induced hemorrhage) puts the infant at risk for prematurity-related complications.

8. Is MRI always necessary?

No. MRI is a secondary tool used when ultrasound is inconclusive, particularly to determine the extent of invasion into the bladder or pelvic sidewalls.

9. What is the biggest danger during surgery?

Uncontrolled hemorrhage and the subsequent cascade of DIC (Disseminated Intravascular Coagulation) are the primary causes of maternal mortality.

10. Can I have a normal delivery with a history of Percreta?

No. Once a diagnosis of Percreta is made, a planned cesarean hysterectomy is the only safe delivery method. Future pregnancies are strongly discouraged.

9. Conclusion for Clinical Professionals

Placenta Percreta is a surgical challenge that demands a high index of suspicion and a coordinated, multidisciplinary approach. The shift toward early, systematic screening using TVUS has revolutionized the ability to prepare for these cases. By identifying patients at risk—particularly those with a history of cesarean section and current placenta previa—clinicians can optimize surgical outcomes, minimize blood loss, and ensure the safety of both mother and neonate.

Disclaimer: This guide is intended for educational and clinical reference purposes for healthcare professionals. It does not replace institutional protocols or individualized clinical judgment.